Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice.
This study investigated the anti-obesity effects of fucoxanthin in diet-induced obesity mice fed a high-fat diet (20% fat, wt/wt). The mice were supplemented with two doses of fucoxanthin (0.05 and 0.2%, wt/wt) for 6 wk. Fucoxanthin significantly lowered body weight and visceral fat-pads weights compared with the control group without altering food intake. In epididymal adipose tissue of fucoxanthin-fed mice, adipocyte sizes and mRNA expression of lipogenic and fatty acid beta-oxidation enzymes were significantly altered in a dose-dependent manner. Plasma leptin level was significantly lower in the fucoxanthin groups than in the control group, while the adiponectin level was elevated. Fucoxanthin significantly down-regulated various lipogenic enzyme activities in epididymal adipose tissue with a simultaneous decrease in fatty acid beta-oxidation activity. The 0.2% fucoxanthin supplement led to increase mRNA expression of uncoupling protein-1 (UCP-1) and UCP-3 in brown adipose tissue and that of UCP-2 in the epididymal white adipose tissue. However, the 0.05% fucoxanthin only elevated UCP-1 mRNA expression in epididymal white adipose tissue. These results suggest that the anti-obesity effect of fucoxanthin could be mediated by altering lipid-regulating enzymes and UCPs in the visceral fat tissues and plasma adipokine levels.
Woo
Myoung-Nam
MN
Department of Food Science and Nutrition, Kyungpook National University, Daegu, Republic of Korea.
Jeon
Seon-Min
SM
Shin
Young Chul
YC
Lee
Mi-Kyung
MK
Kang
Mi Ae
MA
Choi
Myung-Sook
MS
D054392:Adipokines / Q000097:blood; D002001:Adipose Tissue, Brown / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage* / Q000302:isolation & purification; D048429:Cell Size; D004041:Dietary Fats / Q000008:administration & dosage; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D007473:Ion Channels / Q000235:genetics / Q000378:metabolism*; D050356:Lipid Metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D024101:Mitochondrial Proteins / Q000235:genetics / Q000378:metabolism*; D009765:Obesity / Q000097:blood / Q000201:enzymology / Q000517:prevention & control; D011897:Random Allocation; D013997:Time Factors; D014475:Uncoupling Agents / Q000378:metabolism*; D000071256:Uncoupling Protein 1; D000071246:Uncoupling Protein 2; D000071247:Uncoupling Protein 3; D044648:Undaria / Q000737:chemistry; D015430:Weight Gain; D024341:Xanthophylls / Q000008:administration & dosage* / Q000302:isolation & purification
D054392:Adipokines; D019440:Anti-Obesity Agents; D004041:Dietary Fats; D007473:Ion Channels; D024101:Mitochondrial Proteins; C000604372:Ucp1 protein, mouse; C000604390:Ucp2 protein, mouse; C000604393:Ucp3 protein, mouse; D014475:Uncoupling Agents; D000071256:Uncoupling Protein 1; D000071246:Uncoupling Protein 2; D000071247:Uncoupling Protein 3; D024341:Xanthophylls; C025164:fucoxanthin